Acute Leukemia in Multiple Myeloma

Publisher Website
Google Scholar
Abstract
Of 476 patients with multiple myeloma treated during a 9 yr period, 11 developed acute myelogenous leukemia or sideroblastic anemia. The myeloma was in remission from chemotherapy with melphalan-prednisone combinations that were continued for a median duration of 3 yr. The incidence of acute leukemia or sideroblastic anemia was about 100 times higher than in normal individuals of the same age. In all patients studied, major cytogenetic abnormalities were present, with hypodiploidy and evidence of chromosomal damage being noted most frequently. The frequency and nature of the chromosome changes were attributed to effects resulting from the prolonged drug therapy. These findings supported the long-term follow-up of selected patients with myeloma without any chemotherapy when marked degrees of remission followed the initial treatment courses.

This publication has 4 references indexed in Scilit: